CASI News and Press, CASI Pharmaceuticals Inc. From 03/04/22

CASI Pharmaceuticals (NASDAQ:CASI) renewed an exclusive distribution agreement under which China Resources Pharmaceutical Commercial Group International Trading Co. will continue to be the sole distributor of Evomela (melphalan) for Injection in China. Evomela is used as a high-dose...

CASI PHARMACEUTICALS ANNOUNCES RENEWAL OF EXCLUSIVE DISTRIBUTION AGREEMENT FOR EVOMELA® IN CHINA PR Newswire ROCKVILLE, Md. and BEIJING , March 4, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focus...

CASI Pharmaceuticals (NASDAQ:CASI) expects EVOMELA revenue of ~$9.12M for Q4 and ~$30M (+100% Y/Y) for FY ended Dec.31,2021 which exceeds the estimated $27M guidance. Analysts consensus estimates for revenues stands at $9.01M while for FY it is seen at $30M. It is targeting FY22 revenue ...

CASI PHARMACEUTICALS ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL-YEAR 2021 REVENUES AND PROVIDES BUSINESS UPDATES Expects to Report EVOMELA® (melphalan for injection) Fourth Quarter 2021 Unaudited Revenue of Approximately $9.12 Million and Full-Year 2021 Unaudited Revenue...

CASI PHARMACEUTICALS PARTNER, BIOINVENT, ANNOUNCES BI -1206 GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA PR Newswire ROCKVILLE, Md and LUND, Sweden , Jan. 20, 2022 /PRNewswire/ -- CASI Pharmace...

CASI PHARMACEUTICALS ANNOUNCES CNCT19 (CD19 CAR-T) GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA PR Newswire ROCKVILLE, Md. and BEIJING , Jan. 18, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused o...

CASI PHARMACEUTICALS, RECEIVES NASDAQ DEFICIENCY NOTICE PR Newswire ROCKVILLE, Md. and BEIJING , Jan. 3, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative...

CASI Pharmaceuticals (NASDAQ:CASI) jumps 12% as board approves a stock repurchase program for the repurchase of up to $10M of the Company's common stock (and no more than 12.5M shares of the Company's common stock) through open market purchases. The funding for this program to come ...

CASI PHARMACEUTICALS ANNOUNCES STOCK REPURCHASE PROGRAM PR Newswire ROCKVILLE, Md. and BEIJING , Dec. 17, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), (the "Company" or "CASI"), a U.S. biopharmaceutical company focused on developing...

LUND, SE / ACCESSWIRE / December 10, 2021 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that the Center for D...